3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
3
Phase 1/2
2
Phase NA
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hematologic Diseases
1
B-cell Malignancies
1
Interventions
Rituximab
23
Cyclophosphamide
11
Radiotherapy
8
Prednisone
8
Vincristine
7
Doxorubicin
7
Lenalidomide
6
Bendamustine Hydrochloride
5
Chlorambucil
4
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
obinutuzumab
2
liposomal amphotericin B
2
idelalisib
2
ibrutinib
2
fludarabine phosphate
2
VAP-cyclo protocol
2
Therapeutics
2
Psychiatric Rehabilitation
2
Levofloxacin
2
Interferon-alpha
2
Idarubicin
2
Epoetin Alfa
2
Early Intervention, Educational
2
Cyclosporine
2
Busulfan
2
zanubrutinib
1
tafasitamab
1
parsaclisib
1
orelabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell, Marginal Zone
×
zanubrutinib
×
Clear all
NCT05100862
2026-05-27
MAHOGANY
BeOne Medicines
Phase 3
Recruiting
780 enrolled